Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Gala Health vs CoreAge Rx

Both scored on the same six-factor Match Score. CoreAge Rx wins this matchup with a 91 to 86 edge.

Gala Health

#5 · Grade B+

Budget-minded patients who want nationwide compounded access now, but like knowing a brand-name and hormone-therapy path sits alongside it.

Visit Gala Health
VS
Higher Match Score

CoreAge Rx

#1 · Grade A−

Anyone who wants transparent flat pricing, fast nationwide access, and no teaser-rate bait-and-switch.

Visit CoreAge Rx

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
90
82
Speed to Start
88
97
Formulary Match
84
80
Support Level
84
93
Flexibility
88
97
Transparency
84
95

Price, coverage & formulary

DetailGala HealthCoreAge Rx
SemaglutideNot disclosed$149/mo
Tirzepatide$179/mo$349/mo
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjectable onlyInjectable only
Match Score86 · B+91 · A−
Winner: CoreAge Rx

CoreAge Rx is our #1-ranked provider overall, and it takes this matchup too — a 91 Match Score to Gala Health's 86. The best all-around match: nationwide access, both molecules at one flat, no-surprise price, and an easy exit.

Gala Health is still a fair pick if its strengths line up with yours — best for: Budget-minded patients who want nationwide compounded access now, but like knowing a brand-name and hormone-therapy path sits alongside it.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Gala Health reviewFull CoreAge Rx review

More head-to-heads

Or browse alternatives to CoreAge Rx and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.